Stratec SE

SBSG.DE has a debt-to-equity ratio of 0.56, indicating a moderate level of leverage, and a current ratio of 3.97, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of -433,000 EUR and free cash flow of -5,172,000 EUR, signaling potential liquidity constraints despite its strong current ratio.

Profitability metrics for SBSG.DE are weak, with a return on equity of -0.001 and a return on assets of -0.0006, both of which are below the industry median for the Advanced Medical Equipment & Technology sector. The company's net income was -242,000 EUR, reflecting a challenging operating environment and potential inefficiencies in cost management.

Geographic and segment exposure data is not available in the provided input, but the company's revenue concentration is not disclosed. Given the nature of the healthcare equipment industry, it is likely that SBSG.DE serves a broad range of customers across multiple regions, though the exact distribution is not specified.

Looking ahead, the company is expected to face continued financial pressure, with no clear indication of revenue growth in the near term. The capital expenditure of -16,230,000 EUR suggests ongoing investment in infrastructure or expansion, but the negative net income and cash flow raise concerns about the sustainability of these investments.

The risk assessment for SBSG.DE highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations without external financing.

Recent events, including analyst estimates, suggest a mixed outlook for SBSG.DE. The mean price target of 30.62 EUR and median price target of 30.50 EUR indicate a cautious but not overly bearish sentiment among analysts. The mean recommendation of 2.14, with two strong-buy and two buy ratings, suggests some confidence in the company's long-term potential despite its current financial challenges.